drugset / Trial / NCT06485713

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

NCT06485713

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.

Timeline

Start
2024-03-01
Primary completion
2026-06-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tipiracil Small molecule
Subject Trifluridine Small molecule
Subject fufuquitinib Unknown

Indications